Implementation and Evaluation of a Social Journey Accompanied in Breast Cancer Diagnosis (EPARS SEIN)

Breast Cancer Clinical Trial

— EPARS-SEIN  

Official title:

Implementation and Evaluation of a Social Journey Accompanied for Women With Breast Cancer Diagnosis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02893527
• Other study ID #: ICM-URC-2014/33
• Status: Terminated
• Phase: N/A
• Start date: February 24, 2015
• Est. completion date: December 2017

Study information

• Verified date: August 2020
• Source: Institut du Cancer de Montpellier - Val d'Aurelle
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate and compare the return to work rate at 12 months

Description:

Evaluate and compare the return to work rate at 12 months (from J1C1 [first day of the first adjuvant chemotherapy regimen]) between the "intervention" group (which has accompanied the career) and the standard group course

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: December 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient major> 18

• Have a diagnosis of localized breast cancer requiring surgery immediately adjuvant therapy sequence including chemotherapy and radiotherapy

• Being more than 3 years of retirement at diagnosis

• Have a work contract valid at the time of diagnosis (before surgery)

• Do not practice a profession

• Be in possession of his rights (excluding guardianship, curatorship)

• Raise the general social security scheme and have rights to cash benefits in the Languedoc-Roussillon region

Exclusion Criteria:

• Patient minor

• Patient diagnosed with metastatic breast cancer

• Patients refusing to sign the consent

• Patients do not have sufficient understanding of the French language

• Patients for whom it is impossible to give clear information

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Behavioral:
• personalized coaching
personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).

Locations

Country	Name	City	State
France	Institut réginal du Cancer de Montpellier	Montpellier

Sponsors (2)

Lead Sponsor	Collaborator
Institut du Cancer de Montpellier - Val d'Aurelle	Cemka-Eval

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate and compare the return to work rate	Evaluate and compare the return to work rate at 12 months (from J1C1 [first day of the first adjuvant chemotherapy regimen]) between the "intervention" group (which has accompanied the career) and the standard group course	through study completion, an average of 5 years
Secondary	describe the conditions of the resumption of work	The study will also allow to describe the conditions of the resumption of work in 12 months for the patients concerned and to compare these conditions between the 2 groups	through study completion, an average of 5 years